CTOs on the Move

Corindus

www.corindus.com

 
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company`s CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.corindus.com
  • 309 Waverley Oaks Road Suite 105
    Waltham, MA USA 02452
  • Phone: 508.653.3335

Executives

Name Title Contact Details

Funding

Corindus raised $45M on 02/28/2017

Similar Companies

BioSphere Medical, Inc.

BioSphere Medical, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Shamrock Marketing De

Shamrock Marketing De is a Chino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wilderness Medical Associates

Wilderness Medical Associates is a Bryant Pond, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revolution Enterprises

Revolution Cannabis is committed to producing the cleanest, most reliable and efficacious medical cannabis products. Our team is comprised of passionate cannabis cultivation, public health, and research professionals united by a desire to cultivate health and happiness through the science of cannabis. Revolution`s core values permeate every facet of operations spanning cultivation, breeding, production, packaging, labeling, community outreach, and more.

BioSig

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.